Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages

  Buti, Sebastiano ^a   Donini, Maddalena ^a   Sergio, Pietro ^a   Garagnani, Lorella ^b   Schirosi, Laura ^b   Passalacqua, Rodolfo ^a   Rossi, Giulio ^b  

^a Azienda Istituti Ospitaleri di Cremona   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN AE1; DOXORUBICIN; EPITHELIAL MEMBRANE ANTIGEN; ETOPOSIDE; GEMCITABINE; IMATINIB; PACLITAXEL; PROTEIN P63; STEM CELL FACTOR RECEPTOR; VINCRISTINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CARCINOMA; CASE REPORT; DRUG ERUPTION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER INJURY; LUNG LESION; MALE; MULTIPLE CYCLE TREATMENT; ONCOGENE C KIT; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSTERNAL PAIN; THYMUS CANCER; THYMUS CARCINOMA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THYMOMA; THYMUS NEOPLASMS;

EID: 81755172128     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.6427     Document Type: Article

References (14)

1. Srirajaskanthan R, Toubanakis C, Dusmet M, et al.: A review of thymic tumours. Lung Cancer 60:4-13, 2008
2. Oguri T, Achiwa H, Kato D, et al.: Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 50:279-282, 2004 (Pubitemid 40069598)
3. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003 (Pubitemid 46621810)
4. van Oosterom AT, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
5. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
6. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Bethesda, MD: National Cancer Institute, 2009
7. Giaccone G, Wilmink H, Paul MA, et al.: Systemic treatment of malignant thymoma. A decade experience at a single institution.AmJ Clin Oncol 29:336-344, 2006 (Pubitemid 44197537)
8. Isozaki K, Hirota S: Gain-of-function mutations of receptor tyrosine kinases in gastrointestinal stromal tumors. Curr Genomics 7:469-475, 2006 (Pubitemid 46062379)
9. Girard N: Thymic tumors: Relevant molecular data in the clinic. J Thorac Oncol 5:S291-S295, 2010 (suppl 4)
10. Ströbel P, Hartmann M, Jakob A, et al.: Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350:2625-2626, 2004 (Pubitemid 38758557)
11. Bisagni G, Rossi G, Cavazza A, et al.: Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 4:773-775, 2009
12. Die̊l U, Oztuzcu S, Bee̊n AA, et al.: Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 71:109-112, 2011
13. Gomes AL, Bardales RH, Milanezi F, et al.: Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 127:89-96, 2007 (Pubitemid 46797023)
14. Curtin JA, Busam K, Pinkel D, et al.: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346, 2006 (Pubitemid 46630793)